

Multiple Agency Fiscal Note Summary

| | |
|--------------------------------|--------------------------|
| Bill Number: 5263 2S SB | Title: Psilocybin |
|--------------------------------|--------------------------|

Estimated Cash Receipts

| Agency Name | 2023-25 | | | 2025-27 | | | 2027-29 | | |
|----------------------------|----------|-------------|---------------|----------|-------------|---------------|----------|-------------|---------------|
| | GF-State | NGF-Outlook | Total | GF-State | NGF-Outlook | Total | GF-State | NGF-Outlook | Total |
| Office of Attorney General | 0 | 0 | 16,000 | 0 | 0 | 16,000 | 0 | 0 | 10,000 |
| Total \$ | 0 | 0 | 16,000 | 0 | 0 | 16,000 | 0 | 0 | 10,000 |

Estimated Operating Expenditures

| Agency Name | 2023-25 | | | | 2025-27 | | | | 2027-29 | | | |
|--|------------|------------------|------------------|------------------|------------|------------------|------------------|------------------|------------|------------------|------------------|------------------|
| | FTEs | GF-State | NGF-Outlook | Total | FTEs | GF-State | NGF-Outlook | Total | FTEs | GF-State | NGF-Outlook | Total |
| Office of Attorney General | .3 | 78,000 | 78,000 | 94,000 | .3 | 78,000 | 78,000 | 94,000 | .3 | 78,000 | 78,000 | 88,000 |
| Washington State Health Care Authority | .0 | 143,000 | 143,000 | 143,000 | .0 | 0 | 0 | 0 | .0 | 0 | 0 | 0 |
| Liquor and Cannabis Board | .3 | 0 | 0 | 84,190 | .3 | 0 | 0 | 78,190 | .3 | 0 | 0 | 78,190 |
| Department of Health | 6.5 | 1,635,000 | 1,635,000 | 1,635,000 | 5.4 | 1,334,000 | 1,334,000 | 1,334,000 | 5.2 | 1,302,000 | 1,302,000 | 1,302,000 |
| Department of Agriculture | .2 | 94,200 | 94,200 | 94,200 | .2 | 94,200 | 94,200 | 94,200 | .2 | 94,200 | 94,200 | 94,200 |
| Total \$ | 7.3 | 1,950,200 | 1,950,200 | 2,050,390 | 6.2 | 1,506,200 | 1,506,200 | 1,600,390 | 6.0 | 1,474,200 | 1,474,200 | 1,562,390 |

| Agency Name | 2023-25 | | | 2025-27 | | | 2027-29 | | |
|---------------------|--|----------|-------|---------|----------|-------|---------|----------|-------|
| | FTEs | GF-State | Total | FTEs | GF-State | Total | FTEs | GF-State | Total |
| Local Gov. Courts | | | | | | | | | |
| Loc School dist-SPI | | | | | | | | | |
| Local Gov. Other | Non-zero but indeterminate cost and/or savings. Please see discussion. | | | | | | | | |
| Local Gov. Total | | | | | | | | | |

Estimated Capital Budget Expenditures

| Agency Name | 2023-25 | | | 2025-27 | | | 2027-29 | | |
|--|------------|----------|----------|------------|----------|----------|------------|----------|----------|
| | FTEs | Bonds | Total | FTEs | Bonds | Total | FTEs | Bonds | Total |
| Office of Attorney General | .0 | 0 | 0 | .0 | 0 | 0 | .0 | 0 | 0 |
| Washington State Health Care Authority | .0 | 0 | 0 | .0 | 0 | 0 | .0 | 0 | 0 |
| Liquor and Cannabis Board | .0 | 0 | 0 | .0 | 0 | 0 | .0 | 0 | 0 |
| Department of Health | .0 | 0 | 0 | .0 | 0 | 0 | .0 | 0 | 0 |
| Department of Agriculture | .0 | 0 | 0 | .0 | 0 | 0 | .0 | 0 | 0 |
| Total \$ | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |

| Agency Name | 2023-25 | | | 2025-27 | | | 2027-29 | | |
|---------------------|--|----------|-------|---------|----------|-------|---------|----------|-------|
| | FTEs | GF-State | Total | FTEs | GF-State | Total | FTEs | GF-State | Total |
| Local Gov. Courts | | | | | | | | | |
| Loc School dist-SPI | | | | | | | | | |
| Local Gov. Other | Non-zero but indeterminate cost and/or savings. Please see discussion. | | | | | | | | |
| Local Gov. Total | | | | | | | | | |

Estimated Capital Budget Breakout

| | | |
|---------------------------------------|---------------------------------|---|
| Prepared by: Breann Boggs, OFM | Phone: (360) 485-5716 | Date Published: Final 3/10/2023 |
|---------------------------------------|---------------------------------|---|

Individual State Agency Fiscal Note

| | | |
|--------------------------------|--------------------------|---|
| Bill Number: 5263 2S SB | Title: Psilocybin | Agency: 100-Office of Attorney General |
|--------------------------------|--------------------------|---|

Part I: Estimates

No Fiscal Impact

Estimated Cash Receipts to:

| ACCOUNT | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|---|---------|---------|---------|---------|---------|
| Legal Services Revolving Account-State 405-1 | 8,000 | 8,000 | 16,000 | 16,000 | 10,000 |
| Total \$ | 8,000 | 8,000 | 16,000 | 16,000 | 10,000 |

Estimated Operating Expenditures from:

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|---|---------|---------|---------|---------|---------|
| FTE Staff Years | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Account | | | | | |
| General Fund-State 001-1 | 39,000 | 39,000 | 78,000 | 78,000 | 78,000 |
| Legal Services Revolving Account-State 405-1 | 8,000 | 8,000 | 16,000 | 16,000 | 10,000 |
| Total \$ | 47,000 | 47,000 | 94,000 | 94,000 | 88,000 |

Estimated Capital Budget Impact:

NONE

The cash receipts and expenditure estimates on this page represent the most likely fiscal impact. Factors impacting the precision of these estimates, and alternate ranges (if appropriate), are explained in Part II.

Check applicable boxes and follow corresponding instructions:

- If fiscal impact is greater than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete entire fiscal note form Parts I-V.
- If fiscal impact is less than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete this page only (Part I).
- Capital budget impact, complete Part IV.
- Requires new rule making, complete Part V.

| | | |
|--------------------------------------|-----------------------|------------------|
| Legislative Contact: Monica Fontaine | Phone: 3607867341 | Date: 02/24/2023 |
| Agency Preparation: Amy Flanigan | Phone: 509-456-3123 | Date: 02/28/2023 |
| Agency Approval: Edd Giger | Phone: 360-586-2104 | Date: 02/28/2023 |
| OFM Review: Cheri Keller | Phone: (360) 584-2207 | Date: 03/01/2023 |

Part II: Narrative Explanation

II. A - Brief Description Of What The Measure Does That Has Fiscal Impact

Significant provisions of the bill and any related workload or policy assumptions that have revenue or expenditure impact on the responding agency by section number.

Section 1: New Section. Legislature establishes advisory board, interagency group and task force to provide advice and recommendations on developing a comprehensive regulatory framework for access to psilocybin for residents over 21.

Section 2: New Section. Purposes.

Section 3: New Section. Name includes Washington Psilocybin Services Act.

Section 4: New Section. Establishes advisory board within the Department of Health (DOH) to provide advice and recommendations to DOH, Liquor and Cannabis Board (LCB), and the Department of Agriculture (AGR). Sets up how advisory board is selected. Also sets up how often board meets. Board may adopt rules and establish committees and subcommittees. Advisory board members can receive reimbursements consistent with RCW 43.03.220.

Section 5: New Section. Establishes interagency work group of DOH, LCB, and AGR to provide advice and recommendation on specified items. Findings of task force created in Section 6 must be submitted to the interagency work group created in this section and the advisory board. Work group must submit regular updates to the advisory board.

Section 6: New Section. The Health Care Authority (HCA) must establish a task force to provide a report on psilocybin services. Sets out membership of task force. HCA must convene first meeting of task force by June 30, 2023 and provide a report by December 1, 2023. Sets out duties of HCA in consultation with task force. Task force meetings must be open to the public. Sets out who is entitled to reimbursements. Section supersedes Section 211(99) chapter 297, Laws of 2022. This section expires June 30, 2024.

Section 7: New Section. Sets out duties, functions and powers of DOH in this chapter.

Section 8: New Section. Medical professional licensed will not be subject to adverse licensing action by recommending psilocybin treatment.

Section 9: New Section. LCB shall assist and cooperate with AGR to carry out duties in this chapter. AGR needs to cooperate with DOH to carry out duties under this chapter.

Section 10: New Section. DOH, AGR, and LCB cannot refuse to act under this chapter on the basis that psilocybin is banned under federal law.

Section 11: New Section. Severability clause.

Section 12: Sections 1 through 5 and 7 through 10 constitute new chapter in Title 8.

Section 13: Sections 4 through 6 take effect immediately.

II. B - Cash receipts Impact

Cash receipts impact of the legislation on the responding agency with the cash receipts provisions identified by section number and when appropriate, the detail of the revenue sources. Description of the factual basis of the assumptions and the method by which the cash receipts impact is derived. Explanation of how workload assumptions translate into estimates. Distinguished between one time and ongoing functions.

Cash receipts are assumed to equal the Legal Services Revolving Account (LSRA) cost estimates. These will be billed through the revolving account to the client agency.

The client agencies are the Department of Health (DOH) and the Liquor and Cannabis Board (LCB). The Attorney General's Office (AGO) will bill all clients for legal services rendered.

These cash receipts represent the AGO's authority to bill and are not a direct appropriation to the AGO. The direct appropriation is reflected in the client agencies' fiscal note. Appropriation authority is necessary in the AGO budget.

AGO AGENCY ASSUMPTIONS:

DOH will be billed for non-Seattle rates:

FY 2024 and FY 2025 (each FY): \$5,000 for 0.02 Assistant Attorney General FTE (AAG) and 0.01 Legal Assistant 3 FTE (LA).

FY 2026 and FY 2027 (each FY): \$8,000 for 0.03 AAG and 0.02 LA.

FY 2028 and each FY thereafter: \$5,000 for 0.02 AAG and 0.01 LA.

LCB will be billed for Seattle rates:

FY 2024 and FY 2025 (each FY): \$3,000 for 0.01 AAG and 0.01 LA.

II. C - Expenditures

Agency expenditures necessary to implement this legislation (or savings resulting from this legislation), with the provisions of the legislation that result in the expenditures (or savings) identified by section number. Description of the factual basis of the assumptions and the method by which the expenditure impact is derived. Explanation of how workload assumptions translate into cost estimates. Distinguished between one time and ongoing functions.

Attorney General's Office (AGO) Agency Assumptions:

This bill is effective immediately due to an emergency clause.

Location of staffing is assumed to be in a Seattle and non-Seattle office building.

Total workload impact in this request includes standard assumption costs for goods & services, travel, and capital outlays for all FTE identified.

Agency administration support FTE are included in the tables. The Management Analyst 5 (MA), is used as a representative classification. An example ratio is for every 1.0 Assistant Attorney General FTE (AAG), the AGO includes 0.5 FTE for a Legal Assistant 3 (LA) and 0.25 FTE of an MA.

Assumptions for the AGO Agriculture & Health Division (AHD) legal services for the Department of Health (DOH):

The AGO will bill DOH for legal services based on the enactment of this bill.

The bill would require some legal advice to the psilocybin advisory board and to DOH on rulemaking pertaining to psilocybin advertising and creation of a psilocybin registry.

AHD total FTE workload impact for non-Seattle:

FY 2024 and FY 2025 (each FY): \$5,000 for 0.02 AAG and 0.01 LA.

FY 2026 and FY 2027 (each FY): \$8,000 for 0.03 AAG and 0.02 LA.

FY 2028 and each FY thereafter: \$5,000 for 0.02 AAG and 0.01 LA.

Assumptions for the AGO Licensing & Administrative Law Division (LAL) legal services for the Liquor and Cannabis Board (LCB):

The AGO will bill LCB for legal services based on the enactment of this bill.

LAL provides legal advice to the LCB, including advice on rulemaking and contract and procurement work.

This bill imposes limited new responsibilities on LCB, and imposes no licensing or enforcement requirements on LCB.

LAL total FTE workload impact for Seattle rates:

FY 2024: \$3,000 for 0.01 AAG and 0.01 LA.

FY 2025: \$3,000 for 0.01 AAG and 0.01 LA.

Assumptions for the AGO Administrative Division (ADM):

AGO ADM activities are funded with General Fund-State dollars. There is no appropriate client agency to bill for legal services.

ADM assumes the enactment of this bill will require 0.25 Policy Analyst (Exempt) FTE (PA) for an ongoing participation in and contributions to the psilocybin board.

ADM total FTE workload impact for Seattle rates:

FY 2024: \$39,000 for 0.25 PA and each FY thereafter.

The AGO Criminal Justice Division (CRJ) has reviewed this bill and determined it will not significantly increase or decrease the division's workload in representing the Washington State Patrol (WSP). Prior references to WSP have been removed from this bill. The enactment of this bill will not impact the investigative or prosecutorial work of CRJ. Therefore, costs are not included in this request.

The AGO Government Compliance & Enforcement Division (GCE) has reviewed this bill and determined it will not significantly increase or decrease the division's workload in representing LCB. GCE litigates licensing and enforcement actions for LCB. Section 4 of this bill would require the appointment of a member of LCB to the psilocybin advisory board. Section 5 would create an interagency psilocybin work group, which would require LCB to provide advice and recommendations to the advisory board. Section 6 would require the Health Care Authority (HCA) to establish a psilocybin task force, and the appointment of a LCB member to the task force. Section 9 would require LCB to assist and cooperate with DOH and the Washington State Department of Agriculture (WSDA) as necessary for the departments to carry out their duties under this bill. Because LCB would have no regulatory authority under this bill, GCE does not anticipate this bill would result in any litigation that would impact GCE. Therefore, costs are not included in this request.

The AGO GCE Division has reviewed this bill and determined it will not significantly increase or decrease the division's workload in representing DOH. GCE litigates disciplinary actions for certain boards and commissions supported by DOH. Section 7 of this bill would give DOH the necessary powers and duties related to psilocybin products and services. Section 8 would exempt medical professionals licensed in Washington State from adverse licensing action for recommending psilocybin treatments. DOH would have regulatory authority over the products and services allowed by this bill. This would exclude the boards and commissions represented by GCE. Therefore, GCE does not anticipate any new work as a result of this bill, and costs are not included in this request.

The AGO Civil Rights Division (CRD) has reviewed this bill and determined it will not significantly increase or decrease the division's workload in representing the Human Rights Commission (HRC). New legal services are nominal and costs are not included in this request.

The AGO Social & Health Services – Olympia Division (SHO) has reviewed this bill and determined it will not significantly increase or decrease the division’s workload. The enactment of this bill will not impact the provision of legal services to HCA. HCA is tasked with setting up a task force to study various aspects of psilocybin services, including various clinical issues. SHO does not anticipate HCA needing to seek legal advice regarding the task force. Any unanticipated inquiries would be part of the regular course of legal advice provided to HCA. New legal services are nominal and costs are not included in this request.

AHD, LAL, and ADM total FTE workload impact for Seattle and non-Seattle rates:

FY 2024 – FY 2027 (each FY): \$47,000 for 0.03 AAG, 0.02 LA and 0.25 PA.
 FY 2028 and each FY thereafter: \$44,000 for 0.02 AAG, 0.01 LA, and 0.25 PA.

Part III: Expenditure Detail

III. A - Operating Budget Expenditures

| Account | Account Title | Type | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|-----------------|-------------------------------------|-------|---------|---------|---------|---------|---------|
| 001-1 | General Fund | State | 39,000 | 39,000 | 78,000 | 78,000 | 78,000 |
| 405-1 | Legal Services Revolving Account | State | 8,000 | 8,000 | 16,000 | 16,000 | 10,000 |
| Total \$ | | | 47,000 | 47,000 | 94,000 | 94,000 | 88,000 |

III. B - Expenditures by Object Or Purpose

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|----------------------------|---------|---------|---------|---------|---------|
| FTE Staff Years | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| A-Salaries and Wages | 32,000 | 32,000 | 64,000 | 64,000 | 60,000 |
| B-Employee Benefits | 10,000 | 10,000 | 20,000 | 20,000 | 18,000 |
| E-Goods and Other Services | 5,000 | 5,000 | 10,000 | 10,000 | 10,000 |
| Total \$ | 47,000 | 47,000 | 94,000 | 94,000 | 88,000 |

III. C - Operating FTE Detail: *List FTEs by classification and corresponding annual compensation. Totals need to agree with total FTEs in Part I and Part IIIA*

| Job Classification | Salary | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|------------------------------------|---------|---------|---------|---------|---------|---------|
| Assistant Attorney General | 118,700 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Assistant Attorney General-Seattle | 124,635 | 0.0 | 0.0 | 0.0 | | |
| Legal Assistant 3 | 55,872 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Legal Assistant 3-Seattle | 67,044 | 0.0 | 0.0 | 0.0 | | |
| Management Analyst 5 | 91,524 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Policy Analyst (Exempt) | 95,000 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Total FTEs | | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |

III. D - Expenditures By Program (optional)

| Program | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|---|---------|---------|---------|---------|---------|
| Headquarters Administration GFS (ADM) | 39,000 | 39,000 | 78,000 | 78,000 | 78,000 |
| Agriculture & Health Division (AHD) | 5,000 | 5,000 | 10,000 | 16,000 | 10,000 |
| Licensing & Administrative Law Division (LAL) | 3,000 | 3,000 | 6,000 | | |
| Total \$ | 47,000 | 47,000 | 94,000 | 94,000 | 88,000 |

Part IV: Capital Budget Impact

IV. A - Capital Budget Expenditures

NONE

IV. B - Expenditures by Object Or Purpose

NONE

IV. C - Capital Budget Breakout

Acquisition and construction costs not reflected elsewhere on the fiscal note and description of potential financing methods.

NONE

IV. D - Capital FTE Detail: *FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part IVB.*

NONE

Part V: New Rule Making Required

Provisions of the bill that require the agency to adopt new administrative rules or repeal/revise existing rules.

Individual State Agency Fiscal Note

| | | |
|--------------------------------|--------------------------|---|
| Bill Number: 5263 2S SB | Title: Psilocybin | Agency: 107-Washington State Health Care Authority |
|--------------------------------|--------------------------|---|

Part I: Estimates

No Fiscal Impact

Estimated Cash Receipts to:

NONE

Estimated Operating Expenditures from:

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|--------------------------|---------|---------|---------|---------|---------|
| Account | | | | | |
| General Fund-State 001-1 | 143,000 | 0 | 143,000 | 0 | 0 |
| Total \$ | 143,000 | 0 | 143,000 | 0 | 0 |

Estimated Capital Budget Impact:

NONE

The cash receipts and expenditure estimates on this page represent the most likely fiscal impact. Factors impacting the precision of these estimates, and alternate ranges (if appropriate), are explained in Part II.

Check applicable boxes and follow corresponding instructions:

- If fiscal impact is greater than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete entire fiscal note form Parts I-V.
- If fiscal impact is less than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete this page only (Part I).
- Capital budget impact, complete Part IV.
- Requires new rule making, complete Part V.

| | | |
|--------------------------------------|-----------------------|------------------|
| Legislative Contact: Monica Fontaine | Phone: 3607867341 | Date: 02/24/2023 |
| Agency Preparation: Hanh OBrien | Phone: 360-725-1447 | Date: 03/01/2023 |
| Agency Approval: Catrina Lucero | Phone: 360-725-7192 | Date: 03/01/2023 |
| OFM Review: Arnel Blancas | Phone: (360) 000-0000 | Date: 03/03/2023 |

Part II: Narrative Explanation

II. A - Brief Description Of What The Measure Does That Has Fiscal Impact

Significant provisions of the bill and any related workload or policy assumptions that have revenue or expenditure impact on the responding agency by section number.

See attached narrative.

II. B - Cash receipts Impact

Cash receipts impact of the legislation on the responding agency with the cash receipts provisions identified by section number and when appropriate, the detail of the revenue sources. Description of the factual basis of the assumptions and the method by which the cash receipts impact is derived. Explanation of how workload assumptions translate into estimates. Distinguished between one time and ongoing functions.

See attached narrative.

II. C - Expenditures

Agency expenditures necessary to implement this legislation (or savings resulting from this legislation), with the provisions of the legislation that result in the expenditures (or savings) identified by section number. Description of the factual basis of the assumptions and the method by which the expenditure impact is derived. Explanation of how workload assumptions translate into cost estimates. Distinguished between one time and ongoing functions.

See attached narrative.

Part III: Expenditure Detail

III. A - Operating Budget Expenditures

| Account | Account Title | Type | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|-----------------|---------------|-------|---------|---------|---------|---------|---------|
| 001-1 | General Fund | State | 143,000 | 0 | 143,000 | 0 | 0 |
| Total \$ | | | 143,000 | 0 | 143,000 | 0 | 0 |

III. B - Expenditures by Object Or Purpose

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|--------------------------------------|---------|---------|---------|---------|---------|
| FTE Staff Years | | | | | |
| A-Salaries and Wages | | | | | |
| B-Employee Benefits | | | | | |
| C-Professional Service Contracts | 143,000 | | 143,000 | | |
| E-Goods and Other Services | | | | | |
| G-Travel | | | | | |
| J-Capital Outlays | | | | | |
| M-Inter Agency/Fund Transfers | | | | | |
| N-Grants, Benefits & Client Services | | | | | |
| P-Debt Service | | | | | |
| S-Interagency Reimbursements | | | | | |
| T-Intra-Agency Reimbursements | | | | | |
| 9- | | | | | |
| Total \$ | 143,000 | 0 | 143,000 | 0 | 0 |

III. C - Operating FTE Detail: FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part I and Part IIIA.

NONE

III. D - Expenditures By Program (optional)

NONE

Part IV: Capital Budget Impact

IV. A - Capital Budget Expenditures

NONE

IV. B - Expenditures by Object Or Purpose

NONE

IV. C - Capital Budget Breakout

Acquisition and construction costs not reflected elsewhere on the fiscal note and description of potential financing methods.

NONE

IV. D - Capital FTE Detail: *FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part IVB.*

NONE

Part V: New Rule Making Required

Provisions of the bill that require the agency to adopt new administrative rules or repeal/revise existing rules.

HCA Fiscal Note

Bill Number: 5263 2SSB

HCA Request #: 23-172

Part II: Narrative Explanation

II. A - Brief Description Of What The Measure Does That Has Fiscal Impact

An ACT Relating to access to psilocybin services by individuals 21 years of age and older.

The second substitute bill makes the following changes from the first substitute bill:

- Section 1 adds a task force to provide advice and recommendations on developing comprehensive regulatory framework.
- Removes sections 4 and 5.
- Section 4(6) changes date from July 1, 2025 to July 1, 2024, during this time the Advisory Board must meet at least five times.
- Section 6 (formally section 8):
 - (3) Changes the final report date submitted to the governor and appropriate committees of the legislature by to December 1, 2023, in accordance with RCW 43.01.036;
 - (8) Adds intent of the legislature that the provisions of this section supersede section 211(99), chapter 297, Laws of 2022;
 - (9) Adds this section expires June 30, 2024.
- Section 8 (formally section 10) removes “psilocybin patients is protected from criminal, civil, or adverse licensing action in Washington for the mere use of psilocybin.”
- Removes section 11 from previous bill DOH to develop a registry for individuals over 21 who are interested in using psilocybin by July 1, 2028.

Section 6 renames the psilocybin stakeholder group created in the 2022 Supplemental Operating Budget, Section 211(99), to a Task Force and makes the following additional changes:

- Replaces a member of the nursing profession with knowledge of psilocybin with a public health practitioner;
- Specifies two psychologists, two mental health counselors, and two physicians with experience in mental and behavioral health, or experience in palliative care are included on the Task Force,
- Adds a pharmacologist with expertise in psychopharmacology;
- Specifies that the cannabis industry representative must have knowledge of medical cannabis;
- The Health Care Authority (HCA) must convene the first meeting of the Task Force no later than June 30, 2023;
- HCA must provide a final report to the governor and appropriate committees of the legislature by December 1, 2023;
- Expands the duties of HCA in consultation with the Task Force to include, among other things, activities regarding clinical trials and research, and reviewing and discussing regulatory structures for clinical use of psilocybin in Oregon and other jurisdictions;
- Adds intent of the legislature that the provisions of this section supersede section 211(99), chapter 297, Laws of 2022;
- Adds expiration date of June 30, 2024.

II. B - Cash Receipts Impact

None

II. C – Expenditures

Fiscal impact. HCA requests \$143,000 GF-S in 2023-25 biennium.

HCA Fiscal Note

Bill Number: 5263 2SSB

HCA Request #: 23-172

Section 6 renames the psilocybin stakeholder group that was funded in 2022 Supplemental Operating Budget to the Task Force and extends the Task Force meeting. The bill requires HCA to convene the first meeting of the Task Force no later than June 30, 2023 and to provide the final report to the governor and legislature by December 1, 2023. Currently, HCA holds a contract with Oregon Health and Science University (OHSU) for \$203,000 GF-S in fiscal year 2023 to help facilitate the workgroup and complete the report. HCA would need to extend the contract with OHSU to continue work required in the Task Force and to ensure the topics noted in the section 6(4) will be captured within the final report.

By Fund:

II. C - Operating Budget Expenditures

| Account | Account Title | Type | FY-2024 | FY-2025 | 2023-25 | 2025-27 | 2027-29 |
|---------------|---------------|-------|-------------------|-------------|-------------------|-------------|-------------|
| 001-1 | General Fund | State | 143,000 | - | 143,000 | - | - |
| Totals | | | \$ 143,000 | \$ - | \$ 143,000 | \$ - | \$ - |

By Object:

II. C - Expenditures by Object Or Purpose

| | | | FY-2024 | FY-2025 | 2023-25 | 2025-27 | 2027-29 |
|---------------|--------------------------------|--|-------------------|-------------|-------------------|-------------|-------------|
| C | Professional Service Contracts | | 143,000 | - | 143,000 | - | - |
| Totals | | | \$ 143,000 | \$ - | \$ 143,000 | \$ - | \$ - |

Part IV: Capital Budget Impact

None

Part V: New Rule Making Require

None

Individual State Agency Fiscal Note

| | | |
|--------------------------------|--------------------------|--|
| Bill Number: 5263 2S SB | Title: Psilocybin | Agency: 195-Liquor and Cannabis Board |
|--------------------------------|--------------------------|--|

Part I: Estimates

No Fiscal Impact

Estimated Cash Receipts to:

NONE

Estimated Operating Expenditures from:

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|---|---------|---------|---------|---------|---------|
| FTE Staff Years | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Account | | | | | |
| Dedicated Cannabis Account-State 315-1 | 42,095 | 42,095 | 84,190 | 78,190 | 78,190 |
| Total \$ | 42,095 | 42,095 | 84,190 | 78,190 | 78,190 |

Estimated Capital Budget Impact:

NONE

The cash receipts and expenditure estimates on this page represent the most likely fiscal impact. Factors impacting the precision of these estimates, and alternate ranges (if appropriate), are explained in Part II.

Check applicable boxes and follow corresponding instructions:

- If fiscal impact is greater than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete entire fiscal note form Parts I-V.
- If fiscal impact is less than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete this page only (Part I).
- Capital budget impact, complete Part IV.
- Requires new rule making, complete Part V.

| | | |
|--------------------------------------|-----------------------|------------------|
| Legislative Contact: Monica Fontaine | Phone: 3607867341 | Date: 02/24/2023 |
| Agency Preparation: Colin O Neill | Phone: (360) 664-4552 | Date: 02/28/2023 |
| Agency Approval: Aaron Hanson | Phone: 360-664-1701 | Date: 02/28/2023 |
| OFM Review: Amy Hatfield | Phone: (360) 280-7584 | Date: 02/28/2023 |

Part II: Narrative Explanation

II. A - Brief Description Of What The Measure Does That Has Fiscal Impact

Significant provisions of the bill and any related workload or policy assumptions that have revenue or expenditure impact on the responding agency by section number.

Section 1. The legislature intends to establish an advisory board and interagency work group to provide advice and recommendations on developing a comprehensive regulatory framework for access to regulated psilocybin for Washington residents who are at least 21 years of age.

Section 2. The legislature declares that the purposes of this chapter are:

- (1) To develop a long-term strategic plan for ensuring that psilocybin services become and remain a safe, accessible, and affordable option for all persons 21 years of age and older in this state for whom psilocybin may be appropriate or as part of their indigenous religious or cultural practices;
- (2) To protect the safety, welfare, health, and peace of the people of this state by prioritizing this state's limited law enforcement resources in the most effective, consistent, and rational way;
- (3) To develop a comprehensive regulatory framework concerning psilocybin products and psilocybin services under state law;
- (4) To prevent the distribution of psilocybin products to other persons who are not permitted to possess psilocybin products under this chapter including but not limited to persons under 21 years of age; and
- (5) To prevent the diversion of psilocybin products from this state to other states.

Section 4.

- (1) The Washington psilocybin advisory board is established within the department to provide advice and recommendations to the department, the liquor and cannabis board, and the department of agriculture.
- (2)(h) The governor shall appoint the following individuals to the Washington psilocybin advisory board: A person designated by the liquor and cannabis board who has experience working with the cannabis central reporting system developed for tracking the transfer of cannabis items.
- (3)(a) Members of the Washington psilocybin advisory board shall serve for a term of four years, but at the pleasure of the governor. Before the expiration of the term of a member, the governor shall appoint a successor whose term begins on January 1st of the following year. A member is eligible for reappointment. If there is a vacancy for any cause, the governor shall make an appointment to become immediately effective for the unexpired term.
- 6) Until July 1, 2024, the Washington psilocybin advisory board shall meet at least five times a calendar year at a time and place determined by the chair or a majority of the voting members of the board. After July 1, 2024, the board shall meet at least once every calendar quarter at a time and place determined by the chair or a majority of the voting members of the board. The board may meet at other times and places specified by the call of the chair or of a majority of the voting members of the board.
- (9) The members of the Washington psilocybin advisory board may receive reimbursement or an allowance for expenses within amounts appropriated for that specific purpose consistent with RCW 43.03.220.

Section 5.

- (1) An interagency psilocybin work group of the department of health, the liquor and cannabis board, and the department of agriculture is created to provide advice and recommendations to the advisory board on the following:
 - (a) Developing a comprehensive regulatory framework for a regulated psilocybin system, including a process to ensure clean and pesticide free psilocybin products;
 - (b) Reviewing indigenous practices with psilocybin, clinical psilocybin trials, and findings;
 - (c) Reviewing research of medical evidence developed on the possible use and misuse of psilocybin therapy; and
 - (d) Ensuring that a social opportunity program is included within any licensing program created under this chapter to remedy the targeted enforcement of drug-related laws on overburdened communities.
- (2) The findings of the psilocybin task force in section 6 of this act must be submitted to the interagency work group created in this section and to the psilocybin advisory board.

(3) The interagency psilocybin work group must submit regular updates to the psilocybin advisory board.

Section 6(3) The health care authority must provide a report to the governor and appropriate committees of the legislature by December 1, 2023. The authority may form subcommittees within the task force and adopt procedures necessary to facilitate its work.

Section 6(4) The duties of the authority in consultation with the task force shall include, but not be limited to, the following activities:

(ia) Reviewing the available clinical information around specific clinical indications for use of psilocybin, including what co-occurring diagnoses or medical and family histories may exclude a person from use of psilocybin. Any review of clinical information should:

(i) Discuss populations excluded from existing clinical trials;

(ii) Discuss factors considered when approval of a medical intervention is approved;

(iii) Consider the diversity of participants in clinical trials and the limitations of each study when applying learnings to the population at large; and

(iv) Identify gaps in the clinical research for the purpose of identifying opportunities for investment by the state for the University of Washington or Washington State University or both to consider studying.

(ii) Reviewing and discussing regulatory structures for clinical use of psilocybin in Washington and other jurisdictions nationally and globally. This should include discussing how various regulatory structures do or do not address concerns around public health and safety the group has identified.

Section 9(1). The liquor and cannabis board shall assist and cooperate with the department of health and the department of agriculture to the extent necessary to carry out the duties of the departments under this chapter.

Section 10. The department, the department of agriculture, and the liquor and cannabis board may not refuse to perform any duty under this chapter on the basis that manufacturing, distributing, dispensing, possessing, or using psilocybin products is prohibited by federal law.

Section 13. Sections 4 through 6 of this act are necessary for the immediate preservation of the public peace, health, or safety, or support of the state government and its existing public institutions, and take effect immediately.

CHANGES MADE BY THE SECOND SUBSTITUTE:

- Section 4(6) Requires the Psilocybin Advisory Board to meet at least five times per calendar year until July 1, 2024 (rather than July 1, 2025), and at least once per calendar quarter after July 1, 2024 (rather than July 1, 2025).
- Section 6(1) - Creates a Psilocybin Task Force (Task Force) in the bill rather than amending a 2022 Supplemental Operating Budget section and including the section in the bill.
- Section 6(2) - Removes the Task Force's preliminary report requirement and moves up the deadline for the final report to December 1, 2023, from December 1, 2024, which was the original deadline in the budget, and expires the Task Force on June 30, 2024.
- Removes a number of other sections and subsections in the bill referencing psilocybin licenses, services, and products in the original bill that are no longer contained in the substitute bill.
- Removes other provisions including, among others, provisions relating to: directing the Department of Health (DOH) to develop a psilocybin registry; granting DOH certain duties, functions, and powers relating to license fees and psilocybin product advertising, which are no longer contained in the substitute bill; and protecting medical professionals and psilocybin patients for certain actions related to psilocybin.

II. B - Cash receipts Impact

Cash receipts impact of the legislation on the responding agency with the cash receipts provisions identified by section number and when appropriate, the detail of the revenue sources. Description of the factual basis of the assumptions and the method by which the cash receipts impact is derived. Explanation of how workload assumptions translate into estimates. Distinguished between one time and ongoing functions.

II. C - Expenditures

Agency expenditures necessary to implement this legislation (or savings resulting from this legislation), with the provisions of the legislation that result in the expenditures (or savings) identified by section number. Description of the factual basis of the assumptions and the method by which the expenditure impact is derived. Explanation of how workload assumptions translate into cost estimates. Distinguished between one time and ongoing functions.

With respect to the advisory board, the bill provides that the governor will appoint someone designated by the Washington State Liquor and Cannabis Board ("LCB") with experience in the Cannabis Central Reporting System (CCRS) to a four year term with some specific requirements (the advisory board meets at least five times a year and potentially other times where ever the chair or a majority of the advisory board wishes). Fiscal impact here would likely be FTE time devoted to advisory board work that might necessitate some existing workflow coordination. The agency believes this impact could likely be absorbed within existing resources and the bill provides for reimbursement of expenses.

With respect to the interagency work group fiscal impact would be significantly greater based on the described responsibilities (regulatory development for example) of the LCB designee. This group would report to the advisory board on an on-going basis, so it's possible that meetings would be more frequent than the advisory board.

With respect to the psilocybin task force, a report would be due to the legislature by Dec 1 2023, so assuming significant LCB contributions may be needed here, as well, although the cost of the report itself is covered in the bill, but staff time is not.

The agency assumes the roles as described for the second two bodies would have significant impact in terms of time needed to complete the work.

0.3 FTE Regulatory Analyst 3 - \$39,095/yr (\$38,264 salary/benefits, \$831 in associated costs).

The Attorney General's Office will bill the agency for legal services based on the enactment of this bill. This bill imposes limited new responsibilities on the agency and imposes no licensing or enforcement requirements. Therefore, some legal services will be required. This bill does not require the agency to do more than cooperate and consult with the Department of Health to formulate rules and plan to effectuate the bill.

FY 2024: \$3,000

FY 2025: \$3,000

Part III: Expenditure Detail

III. A - Operating Budget Expenditures

| Account | Account Title | Type | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|-----------------|----------------------------|-------|---------|---------|---------|---------|---------|
| 315-1 | Dedicated Cannabis Account | State | 42,095 | 42,095 | 84,190 | 78,190 | 78,190 |
| Total \$ | | | 42,095 | 42,095 | 84,190 | 78,190 | 78,190 |

III. B - Expenditures by Object Or Purpose

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|--------------------------------------|---------|---------|---------|---------|---------|
| FTE Staff Years | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| A-Salaries and Wages | 28,847 | 28,847 | 57,694 | 57,694 | 57,694 |
| B-Employee Benefits | 9,417 | 9,417 | 18,834 | 18,834 | 18,834 |
| C-Professional Service Contracts | | | | | |
| E-Goods and Other Services | 3,789 | 3,789 | 7,578 | 1,578 | 1,578 |
| G-Travel | | | | | |
| J-Capital Outlays | 42 | 42 | 84 | 84 | 84 |
| M-Inter Agency/Fund Transfers | | | | | |
| N-Grants, Benefits & Client Services | | | | | |
| P-Debt Service | | | | | |
| S-Interagency Reimbursements | | | | | |
| T-Intra-Agency Reimbursements | | | | | |
| 9- | | | | | |
| Total \$ | 42,095 | 42,095 | 84,190 | 78,190 | 78,190 |

III. C - Operating FTE Detail: *List FTEs by classification and corresponding annual compensation. Totals need to agree with total FTEs in Part I and Part IIIA*

| Job Classification | Salary | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|----------------------|--------|---------|---------|---------|---------|---------|
| Regulatory Analyst 3 | 96,156 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Total FTEs | | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |

III. D - Expenditures By Program (optional)

| Program | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|----------------------|---------|---------|---------|---------|---------|
| Board Division (010) | 42,095 | 42,095 | 84,190 | 78,190 | 78,190 |
| Total \$ | 42,095 | 42,095 | 84,190 | 78,190 | 78,190 |

Part IV: Capital Budget Impact

IV. A - Capital Budget Expenditures

NONE

IV. B - Expenditures by Object Or Purpose

NONE

IV. C - Capital Budget Breakout

Acquisition and construction costs not reflected elsewhere on the fiscal note and description of potential financing methods.

NONE

IV. D - Capital FTE Detail: *FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part IVB.*

NONE

Part V: New Rule Making Required

Provisions of the bill that require the agency to adopt new administrative rules or repeal/revise existing rules.

Individual State Agency Fiscal Note

| | | |
|--------------------------------|--------------------------|---|
| Bill Number: 5263 2S SB | Title: Psilocybin | Agency: 303-Department of Health |
|--------------------------------|--------------------------|---|

Part I: Estimates

No Fiscal Impact

Estimated Cash Receipts to:

NONE

Estimated Operating Expenditures from:

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|-------------------------------|---------|---------|-----------|-----------|-----------|
| FTE Staff Years | 7.4 | 5.5 | 6.5 | 5.4 | 5.2 |
| Account | | | | | |
| General Fund-State 001-1 | 952,000 | 683,000 | 1,635,000 | 1,334,000 | 1,302,000 |
| Total \$ | 952,000 | 683,000 | 1,635,000 | 1,334,000 | 1,302,000 |

Estimated Capital Budget Impact:

NONE

The cash receipts and expenditure estimates on this page represent the most likely fiscal impact. Factors impacting the precision of these estimates, and alternate ranges (if appropriate), are explained in Part II.

Check applicable boxes and follow corresponding instructions:

- If fiscal impact is greater than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete entire fiscal note form Parts I-V.
- If fiscal impact is less than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete this page only (Part I).
- Capital budget impact, complete Part IV.
- Requires new rule making, complete Part V.

| | | |
|--------------------------------------|-----------------------|------------------|
| Legislative Contact: Monica Fontaine | Phone: 3607867341 | Date: 02/24/2023 |
| Agency Preparation: Donna Compton | Phone: 360-236-4538 | Date: 03/01/2023 |
| Agency Approval: Kristin Bettridge | Phone: 3607911657 | Date: 03/01/2023 |
| OFM Review: Breann Boggs | Phone: (360) 485-5716 | Date: 03/01/2023 |

Part II: Narrative Explanation

II. A - Brief Description Of What The Measure Does That Has Fiscal Impact

Significant provisions of the bill and any related workload or policy assumptions that have revenue or expenditure impact on the responding agency by section number.

The fiscal impact on this version of the bill has changed from the previous version SSB 5263 . This version changes meeting frequency requirements for the Washington Psilocybin Advisory Board and removes other provisions, including those requiring the Department of Health develop a registry.

This bill adds a new chapter to Title 18 RCW, establishing an advisory board and interagency work group, and a task force to provide advice and recommendations on developing a comprehensive regulatory framework for access to regulated psilocybin for Washington residents who are at least 21 years of age.

Section 4: Establishes the Washington Psilocybin Advisory Board (board) within the department to provide advice and recommendations to the department, the Liquor and Cannabis Board (LCB), and the Department of Agriculture (AGR). The advisory board shall consist of 19 - 21 members. The board must meet at least five times per calendar year until July 1, 2024, and at least once every calendar quarter each year thereafter. The members of the board may receive reimbursement or an allowance for expenses consistent with RCW 43.03.220 (Compensation of members of part-time boards and commissions—Class one groups.).

Section 5: Creates an interagency psilocybin work group (work group) of the department, LCB, and AGR to provide advice and recommendations to the advisory board. The work group must submit regular updates to the board.

Section 7: The department has the duties, functions, and powers necessary or proper to enable the department to carry out its duties, functions, and powers under this chapter, including: 1) To examine, publish, and distribute to the public available studies, research, and other information relating to the safety and efficacy of psilocybin; 2) To adopt, amend, or repeal rules necessary to carry out the intent and provisions of this chapter; and 3) To exercise all powers incidental, convenient, or necessary to enable the department to administer or carry out this chapter.

II. B - Cash receipts Impact

Cash receipts impact of the legislation on the responding agency with the cash receipts provisions identified by section number and when appropriate, the detail of the revenue sources. Description of the factual basis of the assumptions and the method by which the cash receipts impact is derived. Explanation of how workload assumptions translate into estimates. Distinguished between one time and ongoing functions.

II. C - Expenditures

Agency expenditures necessary to implement this legislation (or savings resulting from this legislation), with the provisions of the legislation that result in the expenditures (or savings) identified by section number. Description of the factual basis of the assumptions and the method by which the expenditure impact is derived. Explanation of how workload assumptions translate into cost estimates. Distinguished between one time and ongoing functions.

Board

Section 4: The bill establishes the Washington Psilocybin Advisory Board within the department, made up of 19–21 members. The department anticipates ten (10) work group participants will be community representatives with lived experience who would not otherwise be compensated for their participation. Per RCW 43.03.220 (Compensation of members of part-time boards and commissions—Class one groups), the department will make available stipends of \$200 per meeting to these representatives. The bill requires the board meet at least five times per calendar year until July 1, 2024, and at least once every calendar quarter each year thereafter. Therefore, the department assumes the board will have 5 meetings in FY 2024 and 4 meetings in FY 2025 and each year thereafter. The board must meet at a time and place determined by the chair or a majority of the voting members of the board. In accordance with RCW 43.03.220, the department assumes all meetings will be held virtually in order to not require travel while still maximizing member and public participation. For all meetings, the department anticipates providing meeting announcements and materials in English, Spanish, Russian, and Vietnamese, ASL and Spanish interpretation services, and Communication Access Realtime (CART) will be available for virtual attendees.

The Assistant Attorney General will provide legal advice on board formation and governance and board rulemaking, including attending board meetings. Attorney General Office charges are estimated at \$4,000 each year.

Costs include board stipends, translation, interpretation, CART services, and Assistant Attorney General services:

FY 2024 costs will be \$25,000 (GF-S).

FY 2025 and ongoing, costs will be \$20,000 (GF-S) each year.

Work Group

Section 5: Department staff will be required to participate in the interagency psilocybin work group, providing advice and recommendations to the board on developing a comprehensive regulatory framework for a regulated psilocybin system, reviewing indigenous practices, clinical trials, findings, and research of medical evidence related to psilocybin, and ensuring that a social opportunity program is included within any psilocybin licensing program. The department assumes work in FY 2024 will be primarily focused on researching and reviewing clinical trials, findings, and available medical research and reporting this information to the board. The department assumes work in FY 2025 and FY 2026 will be focused on developing and providing recommendations on the development of a regulatory framework and a social opportunity program, as well as continued review of available research. Ongoing, staff will be required to further develop and provide recommendations to the board.

Costs include staff and associated expenses (goods and services, intra-agency, and indirect charges) for the following:

- Science Officer: 2.0 FTE in FY 2024, 0.5 FTE each year thereafter.
- Regulatory Framework Subject Matter Expert: 1.0 FTE ongoing.
- Equity & Community Engagement Specialist: 0.3 FTE in FY 2024; 0.5 FTE in FY 2025 and FY 2026; 0.3 FTE ongoing

FY 2024 costs will be 4.7 FTE and \$615,000 (GF-S).

FY 2025 costs will be 2.8 FTE and \$348,000 (GF-S).

FY 2026 costs will be 2.8 FTE and \$348,000 (GF-S).

FY 2027 and ongoing, costs will be 2.5 FTE and \$316,000 (GF-S) each year.

Staff Support

Sections 4, 5, and 7: The department will hire staff to support the board and the work group, including coordination of meetings, drafting of formal recommendations made by the board to the department, LCB, and AGR, and other administrative duties, including coordination of board stipends. Additionally, staff will be required to draft and publish materials for the public and answer questions from the public and interested parties related to the board, work group, and department's work with psilocybin.

Costs includes staff and associated expenses (goods and services, intra-agency, and indirect charges) for the following:

- Psilocybin Work Group and Staff Support Manager: 0.25 FTE ongoing
- Work Group and Advisory Board Support: 1.25 FTE ongoing
- Administrative Assistant: 0.5 FTE ongoing

FY 2024 costs will be 2.7 FTE and \$312,000 (GF-S).

FY 2025 and ongoing, costs will be 2.7 FTE and \$315,000 (GF-S) each year.

Rulemaking

Section 7: The bill gives the department authority to adopt, amend, or repeal rules necessary to carry out the intent and provisions of this chapter. The department does not anticipate adopting any rules to implement this bill, therefore there is no assumed fiscal impact for rulemaking.

TOTAL COSTS TO IMPLEMENT THIS BILL:

FY 2024 costs will be 7.4 FTE and \$952,000 (GF-S).

FY 2025 costs will be 5.5 FTE and \$683,000 (GF-S).

FY 2026 costs will be 5.5 FTE and \$683,000 (GF-S).

FY 2027 and ongoing, costs will be 5.2 FTE and \$651,000 (GF-S) each year.

Part III: Expenditure Detail

III. A - Operating Budget Expenditures

| Account | Account Title | Type | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|-----------------|---------------|-------|---------|---------|-----------|-----------|-----------|
| 001-1 | General Fund | State | 952,000 | 683,000 | 1,635,000 | 1,334,000 | 1,302,000 |
| Total \$ | | | 952,000 | 683,000 | 1,635,000 | 1,334,000 | 1,302,000 |

III. B - Expenditures by Object Or Purpose

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|----------------------------------|---------|---------|-----------|-----------|-----------|
| FTE Staff Years | 7.4 | 5.5 | 6.5 | 5.4 | 5.2 |
| A-Salaries and Wages | 615,000 | 440,000 | 1,055,000 | 859,000 | 838,000 |
| B-Employee Benefits | 227,000 | 166,000 | 393,000 | 324,000 | 316,000 |
| C-Professional Service Contracts | 7,000 | 6,000 | 13,000 | 12,000 | 12,000 |
| E-Goods and Other Services | 50,000 | 37,000 | 87,000 | 73,000 | 72,000 |
| J-Capital Outlays | 13,000 | 4,000 | 17,000 | 7,000 | 6,000 |
| T-Intra-Agency Reimbursements | 40,000 | 30,000 | 70,000 | 59,000 | 58,000 |
| Total \$ | 952,000 | 683,000 | 1,635,000 | 1,334,000 | 1,302,000 |

III. C - Operating FTE Detail: *List FTEs by classification and corresponding annual compensation. Totals need to agree with total FTEs in Part I and Part IIIA*

| Job Classification | Salary | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|-----------------------------------|---------|---------|---------|---------|---------|---------|
| ADMINISTRATIVE ASST 3 | 50,592 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| EPIDEMIOLOGIST 3 (NON-MEDICAL) | 108,804 | 2.0 | 0.5 | 1.3 | 0.5 | 0.5 |
| Fiscal Analyst 2 | 53,000 | 1.2 | 0.8 | 1.0 | 0.8 | 0.7 |
| HEALTH SERVICES CONSULTANT 4 | 82,896 | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 |
| Health Svcs Conslt 1 | 53,000 | 0.8 | 0.6 | 0.7 | 0.6 | 0.6 |
| MANAGEMENT ANALYST 4 | 82,896 | 0.3 | 0.5 | 0.4 | 0.4 | 0.3 |
| WMS02 | 114,360 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Total FTEs | | 7.4 | 5.5 | 6.5 | 5.4 | 5.2 |

III. D - Expenditures By Program (optional)

NONE

Part IV: Capital Budget Impact

IV. A - Capital Budget Expenditures

NONE

IV. B - Expenditures by Object Or Purpose

NONE

IV. C - Capital Budget Breakout

Acquisition and construction costs not reflected elsewhere on the fiscal note and description of potential financing methods.

NONE

IV. D - Capital FTE Detail: *FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part IVB.*

NONE

Part V: New Rule Making Required

Provisions of the bill that require the agency to adopt new administrative rules or repeal/revise existing rules.

Individual State Agency Fiscal Note

| | | |
|--------------------------------|--------------------------|--|
| Bill Number: 5263 2S SB | Title: Psilocybin | Agency: 495-Department of Agriculture |
|--------------------------------|--------------------------|--|

Part I: Estimates

No Fiscal Impact

Estimated Cash Receipts to:

NONE

Estimated Operating Expenditures from:

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|-------------------------------|---------|---------|---------|---------|---------|
| FTE Staff Years | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| Account | | | | | |
| General Fund-State 001-1 | 47,100 | 47,100 | 94,200 | 94,200 | 94,200 |
| Total \$ | 47,100 | 47,100 | 94,200 | 94,200 | 94,200 |

Estimated Capital Budget Impact:

NONE

The cash receipts and expenditure estimates on this page represent the most likely fiscal impact. Factors impacting the precision of these estimates, and alternate ranges (if appropriate), are explained in Part II.

Check applicable boxes and follow corresponding instructions:

- If fiscal impact is greater than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete entire fiscal note form Parts I-V.
- If fiscal impact is less than \$50,000 per fiscal year in the current biennium or in subsequent biennia, complete this page only (Part I).
- Capital budget impact, complete Part IV.
- Requires new rule making, complete Part V.

| | | |
|--------------------------------------|-----------------------|------------------|
| Legislative Contact: Monica Fontaine | Phone: 3607867341 | Date: 02/24/2023 |
| Agency Preparation: Trecia Ehrlich | Phone: 360-584-3711 | Date: 02/27/2023 |
| Agency Approval: Jeannie Brown | Phone: 360-902-1989 | Date: 02/27/2023 |
| OFM Review: Matthew Hunter | Phone: (360) 529-7078 | Date: 02/27/2023 |

Part II: Narrative Explanation

II. A - Brief Description Of What The Measure Does That Has Fiscal Impact

Significant provisions of the bill and any related workload or policy assumptions that have revenue or expenditure impact on the responding agency by section number.

2SSB 5263 is the second substitute bill for SB 5263. SB 5263 is an act related to access to psilocybin services in a guided clinical setting.

The original bill, SB 5263, creates a legal avenue for the legalization of psilocybin in a guided clinical setting. There were no sections in the original bill that provided WSDA a clear role, however, the bill granted Department of Health the authority to direct WSDA as needed. WSDA was not given a distinct role in the original bill, no fiscal impact could be measured at that time.

SSB 5263, which is the first substitute bill for SB 5263, was essentially an entirely new bill from SB 5263, and instead of creating a program, it created a two year pathway towards a future program. The substitute bill established a psilocybin advisory board and an interagency workgroup that is required to 1) provide advice and recommendations on developing a comprehensive regulatory framework for the legalization of psilocybin and 2) responsible for providing regular updates to the psilocybin advisory board throughout the process. The workgroup would include members from Department of Health (DOH), Department of Agriculture (WSDA), and Liquor Cannabis Board (LCB).

WSDA identified resource needs to include a .20 WMS 2 level policy/analyst staff person to sit on the interagency work group. The position would be ongoing as the requirements of the workgroup are ongoing. Given the work to create a regulatory framework for psilocybin, WSDA also anticipated a need for assistance from the agencies Attorney General's office as it relates to the advice and recommendations WSDA provides the work group.

2SSB 5263 makes the following changes from the first substitute bill:

Sections 4 - federal laws, 5 - definitions, 8 - 2022 Health Care Authority budget were removed Also sections 13, 14, and 16 through 24 were removed. All other sections were re-numbered.

New Section 4, subsection (6) was amended to require the psilocybin advisory board to meet at least 5 times per calendar year until July 1, 2024 and then at least once every calendar quarter after July 1, 2024.

New Section 6 directs the health care authority to create a separate psilocybin task force to provide a report on psilocybin services, is required to convene by June 30, 2023, and is required to provide a final report to the governor and appropriate legislative committees by December 1, 2023. Under (5) The WSDA is required to provide subject matter expertise and support to the task force and any subcommittee. This new requirement is not a significant change from previous iterations of the bill.

There was no additional language in the second substitute bill to create a timeline for the interagency workgroup, therefore, the changes in the second substitute bill do not change the fiscal impact to WSDA.

II. B - Cash receipts Impact

Cash receipts impact of the legislation on the responding agency with the cash receipts provisions identified by section number and when appropriate, the detail of the revenue sources. Description of the factual basis of the assumptions and the method by which the cash receipts impact is derived. Explanation of how workload assumptions translate into estimates. Distinguished between one time and ongoing functions.

No cash receipts impacts.

II. C - Expenditures

Agency expenditures necessary to implement this legislation (or savings resulting from this legislation), with the provisions of the legislation that result in the expenditures (or savings) identified by section number. Description of the factual basis of the assumptions and the method by which the expenditure impact is derived. Explanation of how workload assumptions translate into cost estimates. Distinguished between one time and ongoing functions.

WSDA estimates a .20 FTE WMS 2 position to be a part of the interagency workgroup for cost of \$39,300 per year and 52 hours of attorney general costs at \$150 per hour for \$7,800 per year. There are no travel costs assumed, as it is assumed that meetings will be held remotely.

Staff costs include salaries, benefits, supplies, and overhead.

Part III: Expenditure Detail

III. A - Operating Budget Expenditures

| Account | Account Title | Type | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|-----------------|---------------|-------|---------|---------|---------|---------|---------|
| 001-1 | General Fund | State | 47,100 | 47,100 | 94,200 | 94,200 | 94,200 |
| Total \$ | | | 47,100 | 47,100 | 94,200 | 94,200 | 94,200 |

III. B - Expenditures by Object Or Purpose

| | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|--------------------------------------|---------|---------|---------|---------|---------|
| FTE Staff Years | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| A-Salaries and Wages | 22,000 | 22,000 | 44,000 | 44,000 | 44,000 |
| B-Employee Benefits | 7,200 | 7,200 | 14,400 | 14,400 | 14,400 |
| C-Professional Service Contracts | | | | | |
| E-Goods and Other Services | 10,600 | 10,600 | 21,200 | 21,200 | 21,200 |
| G-Travel | | | | | |
| J-Capital Outlays | | | | | |
| M-Inter Agency/Fund Transfers | | | | | |
| N-Grants, Benefits & Client Services | | | | | |
| P-Debt Service | 100 | 100 | 200 | 200 | 200 |
| S-Interagency Reimbursements | | | | | |
| T-Intra-Agency Reimbursements | | | | | |
| 9-Agency Admin Overhead | 7,200 | 7,200 | 14,400 | 14,400 | 14,400 |
| Total \$ | 47,100 | 47,100 | 94,200 | 94,200 | 94,200 |

III. C - Operating FTE Detail: *List FTEs by classification and corresponding annual compensation. Totals need to agree with total FTEs in Part I and Part IIIA*

| Job Classification | Salary | FY 2024 | FY 2025 | 2023-25 | 2025-27 | 2027-29 |
|--------------------|---------|---------|---------|---------|---------|---------|
| WMS 2 position | 110,000 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| Total FTEs | | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |

III. D - Expenditures By Program (optional)

NONE

Part IV: Capital Budget Impact

IV. A - Capital Budget Expenditures

NONE

IV. B - Expenditures by Object Or Purpose

NONE

IV. C - Capital Budget Breakout

Acquisition and construction costs not reflected elsewhere on the fiscal note and description of potential financing methods.

NONE

IV. D - Capital FTE Detail: *FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part IVB.*

NONE

Part V: New Rule Making Required

Provisions of the bill that require the agency to adopt new administrative rules or repeal/revise existing rules.

LOCAL GOVERNMENT FISCAL NOTE

Department of Commerce

Bill Number: 5263 2S SB

Title: Psilocybin

Part I: Jurisdiction-Location, type or status of political subdivision defines range of fiscal impacts.

Legislation Impacts:

- Cities: Public health employees could be appointed to the psilocybin work group, task force or advisory board
- Counties: Same as above
- Special Districts: Public hospital employees could be appointed to the psilocybin work group, task force or advisory board
- Specific jurisdictions only:
- Variance occurs due to:

Part II: Estimates

- No fiscal impacts.
- Expenditures represent one-time costs:
- Legislation provides local option:
- Key variables cannot be estimated with certainty at this time: If public hospital or local government public health employees will be appointed to the work group or task force; the amount of work hours required to fulfill work group or task force duties

Estimated revenue impacts to:

None

Estimated expenditure impacts to:

Non-zero but indeterminate cost and/or savings. Please see discussion.

Part III: Preparation and Approval

| | | |
|---|-----------------------|------------------|
| Fiscal Note Analyst: Brandon Rountree | Phone: (360) 999-7103 | Date: 03/08/2023 |
| Leg. Committee Contact: Monica Fontaine | Phone: 3607867341 | Date: 02/24/2023 |
| Agency Approval: Allan Johnson | Phone: 360-725-5033 | Date: 03/08/2023 |
| OFM Review: Breann Boggs | Phone: (360) 485-5716 | Date: 03/10/2023 |

Part IV: Analysis

A. SUMMARY OF BILL

Description of the bill with an emphasis on how it impacts local government.

Overview: Establishes an advisory board within the Department of Health (DOH) to provide advice and recommendations to DOH, the Liquor and Cannabis Board (LCB), and the Washington State Department of Agriculture (WSDA), consisting of agency members and other specified members appointed by the Governor. Creates an interagency work group of DOH, LCB, and WSDA to provide advice and recommendations, in regular updates, to the advisory board on developing a comprehensive regulatory framework for a regulated psilocybin system, and other specified topics. Requires the Health Care Authority to establish a Psilocybin Task Force, which must provide a final report to the Governor and Legislature by December 1, 2023, on specified topics including, without limitation, clinical information on psilocybin use and regulatory structures for clinical psilocybin use in Washington and elsewhere.

Sec. 4: (2) Authorizes the governor to appoint individuals to the Washington psilocybin advisory board.

Sec. 5: (1) Establishes an interagency psilocybin work group between the department of health, the liquor and cannabis board, and the department of agriculture.

Sec. 6: Authorizes the health care authority to establish a psilocybin task force to provide a report on psilocybin services.

B. SUMMARY OF EXPENDITURE IMPACTS

Expenditure impacts of the legislation on local governments with the expenditure provisions identified by section number and when appropriate, the detail of expenditures. Delineated between city, county and special district impacts.

This legislation would have an indeterminate expenditure impact on local governments. The bill calls for the possible participation of public health and public hospital employees in the work group, advisory board and task force, however there is no language which explicitly requires the participation of public health officials from local government or public hospital employees. Additionally, this legislation does not clearly state the amount of work hours it would take an appointed individual to fulfill their duties for the work group, advisory board or task force.

C. SUMMARY OF REVENUE IMPACTS

Revenue impacts of the legislation on local governments, with the revenue provisions identified by section number, and when appropriate, the detail of revenue sources. Delineated between city, county and special district impacts.

This bill would not impact local government revenues. There are no direct revenue impacts on local government or public hospitals.

Source:

Washington State Hospital Association

Senate Bill Report, 2S SB 5263, Labor & Commerce Committee